Search Results
Your search for ,had matches 18486 pages
Showing 7601 - 7650Outcomes in Patients With Retroperitoneal Soft-Tissue Sarcoma by Hospital Type
In a study reported in JCO Oncology Practice, Villano et al found that increased hospital surgical volume was associated with overall improved survival in patients undergoing surgery for retroperitoneal soft-tissue sarcoma. However, increased volume was associated with poorer survival in patients...
Differences in Melanoma Incidence in Men vs Women by Age and Anatomic Site
In a study published by Olsen et al in JAMA Dermatology, researchers found that in predominantly fair-skinned populations, melanoma incidence differed by age and anatomic site in men and women. Methods A cross-sectional analysis of sex- and site-specific trends was performed for white patients...
Neoadjuvant Immunotherapy in Early-Stage Colon Cancer
Patients with localized colon cancer may benefit from a short course of neoadjuvant immunotherapy, according to findings from the exploratory phase II NICHE study published by Myriam Chalabi, MD, and colleagues in Nature Medicine. Study Results Forty patients with two colon cancer subtypes—either ...
Activity of Pembrolizumab in Patients With NSCLC Brain Metastases
As reported in The Lancet Oncology by Sarah B. Goldberg, MD, MPH, and colleagues, continued follow-up of the non–small cell lung cancer (NSCLC) cohort of a single-institution phase II trial showed that pembrolizumab produced responses in patients with brain metastases and programmed cell death...
‘Textbook Outcome’ in Patients Undergoing Resection of Pancreatic Neuroendocrine Tumors
In a study reported in the Journal of Surgical Oncology, Timothy M. Pawlik, MD, MPH, PhD, and colleagues found that approximately half of patients undergoing resection of pancreatic neuroendocrine tumors (PNETs) had a “textbook outcome”—a result associated with significantly improved disease-free...
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
In a retrospective cohort study reported in the Annals of Oncology, Li Zhang, MD, of the Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, and colleagues described characteristics and outcomes of COVID-19 infection in 28 patients with cancer from...
FDA Approves Selumetinib for Pediatric Patients With NF1 and Symptomatic Inoperable Plexiform Neurofibromas
On April 10, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo) for pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic inoperable plexiform neurofibromas. Selumetinib, a kinase inhibitor, is the first therapy approved for...
R. Kate Kelley, MD: Breakthroughs for Hepatocellular Carcinoma
At the University of California, San Francisco School of Medicine, R. Kate Kelley, MD, contributes to research focused on improving outcomes for patients with hepatocellular carcinoma. The trial: This was a phase III study that included 707 patients who received sorafenib and had disease...
From a Single Course, a Far-Reaching Impact Across the Region
It was a great honor for the Russian Society of Clinical Oncology (RUSSCO) to collaborate on the ASCO IPCW, and for me to be a co-organizer of the event from the Russian side. RUSSCO is a professional cancer society with the mission to advance cancer treatment and cures. The organization...
International Palliative Care Workshop in Russia Educates Providers, Improves Care Across Region
ASCO, in collaboration with international oncology societies, hosts International Palliative Care Workshops (IPCWs) designed to teach participants practical skills in patient communication and the management of cancer symptoms and pain. The IPCWs are led by ASCO member volunteers and local experts...
Living A Full Life After Pancreatic Cancer
I have been a radiologic technologist for 47 years, so after going to the bathroom one Sunday morning in October 2018 and finding my urine had suddenly turned dark, I knew something was wrong. I wasn’t in any pain and did not have a urinary tract infection, which would explain the discoloration of...
City of Hope Deploys Platform, Makes Study Data Accessible
A $12 million federal grant enabled City of Hope and collaborators to deploy a novel cloud-computing platform, making an immense amount of data from a historic 25-year study more accessible and user-friendly. The ongoing California Teachers Study, which began in 1995, has already given researchers...
A Hallmark Moment
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
What’s in a Name?
When Narjust Duma, MD, Assistant Professor of Medicine and a thoracic oncologist at the University of Wisconsin Carbone Cancer Center in Madison, presented the findings from her study, “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” during the...
Using Respectful Language to Reduce Unconscious Bias in Oncology Care
An abstract presented at the 2019 ASCO Annual Meeting titled “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” by Narjust Duma, MD, Assistant Professor of Medicine and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center in...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
Updates From Selected Clinical Trials in Breast Cancer
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at 2019 San...
Inspired by Her Physician Father, Reshma Jagsi, MD, DPhil, Tirelessly Advocates for Women’s Health and Careers in Medicine
Physician-scientist, Reshma Jagsi, MD, DPhil, was encouraged by her parents to become a politically active, socially conscious citizen of the world. “As a young woman, my mother traveled from Africa on a scholarship to the United States, where she attended the University of Wisconsin. It was in the ...
SEMA4D Inhibition: A Novel Means of Improving Immune Response
A novel class of inhibitors may hold some promise for boosting responses to checkpoint inhibitors and for sensitizing poorly immunogenic tumors, such as pancreatic cancer, to immunotherapy. The drug targets semaphorin 4D (SEMA4D), a glycoprotein expressed on the cell membranes of many tumor types....
Prior Antibiotic Use Linked to Poorer Survival in Patients With Advanced Melanoma Receiving Immune Checkpoint Inhibitors
Treatment with antibiotics prior to immune checkpoint inhibitor therapy may confer poorer overall survival and an increased risk of colitis in patients with advanced melanoma, according to data presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.1 The largest institutional...
Should Restrictions on Genetic Testing Be Loosened?
The loosening of restrictions on genetic testing would mean that all health-care providers could help move this needle to where it should be, according to Kevin S. Hughes, MD, a surgeon at Massachusetts General Hospital, Professor of Surgery at Harvard Medical School, and Medical Director of the...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Abstracts From the NCCN 2020 Annual Conference Now Available
Abstracts from posters that would have been presented at the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference are now available online. Although NCCN officials were compelled to postpone the conference in response to the coronavirus disease 2019 (COVID-19) pandemic, in order to ...
Study Suggests Adjuvant Everolimus May Benefit Patients With Advanced Head and Neck Cancer
The mTOR inhibitor everolimus, used to treat breast and kidney cancers, may benefit patients with advanced squamous cell carcinoma of the head and neck, according to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.1 The results of an investigator-initiated, phase II...
ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer
ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients with late-stage colorectal cancer.1 “Around the world, there is a huge variation in resources, and what is available to clinicians may change week to week,” said Mary D....
Immunotherapy ‘Comes of Age’ in Breast Cancer
Immunotherapeutics in breast cancer will likely not be limited to late-stage triple-negative breast cancer. Earlier lines, combination regimens, and expansion into different disease subtypes should become part of this emerging landscape, according to Hope S. Rugo, MD, FASCO, Professor of Medicine...
T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...
New Prognostic Score for Asymptomatic Patients With Early-Stage CLL
A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...
Factors Associated With Early Readmissions to Hospital Oncology Services
In a study reported in JCO Oncology Practice, Zibelli et al found that patients with cancer readmitted to hospital within 30 days from index admission often made the decision to return to hospital themselves, without input from their care teams. Study Details The study included 33 patients...
PSA Levels Before Salvage Radiotherapy and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that higher prostate-specific antigen (PSA) pre–salvage radiotherapy (SRT) levels after prostatectomy were associated with better overall survival vs lower levels in men with prostate...
Brief Highlights on Novel Therapies for Prostate, Bladder, and Kidney Cancers
Attendees gathered at the 2020 Genitourinary Cancers Symposium in San Francisco to hear the latest news about treating patients with cancers of the prostate, bladder, kidneys, and testicles. In addition to the comprehensive coverage of the meeting in The ASCO Post, here are some brief highlights...
Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial
In a phase II trial reported in JAMA Oncology, Phillips et al found that stereotactic ablative radiotherapy (SABR) was associated with improved outcomes vs observation in men with oligometastatic prostate cancer. The benefit was augmented in patients with total consolidation of disease identified...
Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab
A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...
Surgical Margins and Survival in Trial of Adjuvant Imatinib for Localized GIST
A post hoc observational study from the phase III EORTC 62024 trial of adjuvant imatinib in patients with localized gastrointestinal stromal tumors (GIST) showed that improvement in survival with R0 vs R1 resection was no longer evident when tumor rupture was excluded from the R1 category. The...
Treatment With Checkpoint Inhibitors May Cause Thyroid Dysfunction
Thyroid dysfunction following treatment with immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting (Abstract SAT-418), and that will be published in Journal of the Endocrine...
Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing
Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...
Methylation Signatures From Sequencing Circulating Cell-Free DNA Detected Different Types of Cancer Across Multiple Stages
Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated—often before there are any clinical signs or symptoms of the disease. These findings were published by Liu et al in Annals of Oncology. In their ...
KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial
In a phase II trial reported in The New England Journal of Medicine, Michael Wang, MD, and colleagues found that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 produced a high response rate in patients with relapsed or refractory mantle cell lymphoma who had received previous...
Clinical Trials to Evaluate Activity of Biologics, Other Agents Against COVID-19
In an effort to expedite research for agents with potential activity against symptoms associated with the novel coronavirus (COVID-19), the U.S. Food and Drug Administration (FDA) is evaluating and/or has approved a number of randomized clinical trials seeking to determine whether a drug has...
Indigenous American Ancestry May Be Associated With HER2-Positive Breast Cancer
An increased proportion of indigenous American ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research.1 “The risk of breast cancer–related mortality varies between different populations, with Latina women having a greater...
Second-Line Lurbinectedin in Small Cell Lung Cancer
As reported in The Lancet Oncology by Trigo et al, second-line treatment with the selective oncogenic transcription inhibitor lurbinectedin showed activity in patients with small cell lung cancer included in a phase II basket trial. The trial includes cohorts representing nine different tumor...
First-in-Human Study of Anteumab Ravtansine for Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Hassan et al found evidence of activity of the anti–mesothelin antibody-drug conjugate anetumab ravtansine in patients with advanced solid tumor types known to express the tumor-differentiation antigen mesothelin. The agent consists...
FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes
On April 3, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) for the treatment of anemia that fails to respond to an erythropoiesis-stimulating agent and requires two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk...
Harvard Medical Student’s Innovation: Disinfection You Can See
In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...
FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations
The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...
Apixaban for Cancer-Associated Venous Thromboembolism
For patients with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low–molecular-weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), with no excess in major bleeding events. These findings from the phase III Caravaggio study were...
Gallium-68 PSMA PET/CT Prior to Surgery or Radiotherapy in High-Risk Prostate Cancer
In an Australian phase III trial (proPSMA) reported in The Lancet, Michael S. Hofman, MBBS, and colleagues found that gallium-68 prostate-specific membrane antigen-11 positron-emission tomography/computed tomography (PSMA PET/CT) provided greater accuracy in identifying nodal and distant metastases ...
Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD
During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...
Factors Associated With Small Adult Height in Childhood Cancer Survivors
In an analysis from the French Childhood Cancer Survivors (CCS) Study reported in the Journal of Clinical Oncology, Demoor-Goldschmidt et al found that receipt of pituitary irradiation, busulfan, and higher doses of lomustine were risk factors for small adult height in survivors of childhood...
Pembrolizumab in Previously Treated Metastatic High-Grade Neuroendocrine Neoplasms
As reported in the British Journal of Cancer by Namrata Vijayvergia, MD, and colleagues, a pooled analysis of two phase II studies found that pembrolizumab monotherapy showed little activity in patients with previously treated metastatic high-grade neuroendocrine neoplasms. Study Details In the...
